Objective: To systematically evaluate the compliance status and influencing factors of menopausal hormone therapy(MHT) in perimenopausal women, in order to provide reference for improving treatment effectiveness and promoting women's health. Method: Computer search was conducted on PubMed, Embase, Ovid, Web of Science, CNKI, Wanfang and other databases for cohort studies and case-control studies on MHT compliance and influencing factors in perimenopausal women. The search period was from the establishment of the database to September 2023. Meta analysis was conducted using Stata 17.0 and Revman 5.3 software. Result: A total of 15 articles were included, total 1 872 people.The Meta-analysis results showed that the MHT compliance rate of perimenopausal women was 62.4%(95%CI:54%-70%), the MHT compliance of perimenopausal women was associated with educational level(OR=0.40,95%CI:0.27-0.57), disease cognition(OR=0.26,95%CI:0.17-0.39), adverse reactions(OR=0.45,95%CI:0.25-0.81), place of residence(OR=0.29,95%CI:0.18-0.46), economic status(OR=0.52,95%CI:0.29-0.95),marital status(OR=0.13,95%CI:0.02-0.87), family support(OR=0.19,95%CI:0.12-0.31), medical insurance expenses(OR=0.24,95%CI:0.7-0.36), medical conditions(OR=0.20,95%CI:0.13-0.32), doctor-patient relationship(OR=0.18,95%CI:0.09-0.34), and psychological status(OR=0.26,95%CI:0.20-0.36). The sensitivity analysis results show that results were relatively stable. Egger's test(P=0.773) showed a lower risk of publication bias in the included literature. Conclusion: MHT compliance rate in perimenopausal women are influenced by education level, disease cognition, adverse reactions, marital status, family support, place of residence, medical conditions, economic status, medical insurance costs, doctor-patient relationship and psychological status. In the future, medical personnel should strengthen health education and publicity, provide personalized treatment plans, strengthen doctor-patient communication, coordinate social and family support, and ensure the compliance and treatment effectiveness of MHT. |
[1] WANG M,KARTSONAKI C,GUO Y,et al.Factors related to age at natural menopause in China:results from the China Kadoorie Biobank[J].Menopause,2021,28(10):1130-1142.
[2] 金志春,黄佳梅,蔡紫璨.更年期综合征中西医结合诊治指南(2023年版)[J].中国实用妇科与产科杂志,2023,39(8):799-808.
[3] 《围绝经期综合征更年期综合征重点人群治未病干预指南》编写组.围绝经期综合征(更年期综合征)重点人群治未病干预指南[J].北京中医药大学学报,2023,46(8):1048-1062.
[4] HUANG Z,SHI J,LIU W,et al.The influence of educational level in peri-menopause syndrome and quality of life among Chinese women[J].Gynecol Endocrinol,2020,36(11):991-996.
[5] 中华预防医学会更年期保健分会.更年期健康管理核心信息专家共识[J].实用妇科内分泌电子杂志,2022,9(1):1-10.
[6] 中华预防医学会妇女保健分会更年期保健学组.更年期妇女保健指南(2015年)[J].实用妇科内分泌杂志(电子版),2016,3(2):21-32.
[7] 陈蓉.《中国绝经管理与绝经激素治疗指南2023版》解读[J].协和医学杂志,2023,14(3):514-519.
[8] 董慧敏,黄俊松,苟芬,等.围绝经期女性绝经激素治疗依从性研究进展[J].中外医学研究,2023,21(11):169-173.
[9] CHU K,SONG Y,CHATOOAH N D,et al.The use and discontinuation of hormone replacement therapy in women in South China[J].Climacteric,2018,21(1):47-52.
[10] 孙星,王燕,郗轶楠,等.激素替代治疗对更年期综合征患者的临床效果及对治疗依从性的影响因素分析[J].中国性科学,2021,30(9):74-76.
[11] 徐安宁.女性更年期综合征患者激素替代治疗依从性及其影响因素分析[J].实用妇科内分泌电子杂志,2021,8(15):122-124.
[12] 尤燕.围绝经期激素补充疗法依从性影响研究[J].实用妇科内分泌电子杂志,2020,7(8):47-48.
[13] STANG A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in Meta-analyses[J].Eur J Epidemiol,2010,25(9):603-605.
[14] 武莉莉,杨娜,辛华,等.抗阻运动对绝经后妇女体成分和肌肉力量影响的Meta分析[J].护士进修杂志,2023,38(16):1490-1493.
[15] 马园园,杜菲菲,马越.影响更年期综合征激素补充治疗依从性相关因素研究[J].健康忠告,2021,15(9):47,49.
[16] 刘小娟,徐舜,陈洁瑛,等.围绝经早期妇女激素替代治疗的用药依从性及其对性器官和激素水平的影响[J].现代实用医学,2020,32(12):1479-1481.
[17] 余晓娟,李雅琴.更年期综合征患者激素替代治疗依从性相关因素分析[J].中国医院统计,2019,26(4):272-274.
[18] 潘利娟.影响更年期综合症激素补充治疗依从性相关因素临床研究[J].临床医药文献电子杂志,2018,5(A0):9-11.
[19] 王小丹.影响更年期综合征激素治疗依从性相关因素及预防对策[J].世界最新医学信息文摘,2018,18(98):33-34.
[20] 盛学娟.围绝经期妇女雌激素替代治疗依从性影响因素研究[J].中国处方药,2018,16(8):1-2.
[21] 朱烨,郑霞.更年期综合征患者激素替代治疗依从性及其影响因素分析[J].医学临床研究,2018,35(1):148-150.
[22] 胡颖敏,王佩英,汤丽芬,等.激素治疗围绝经期综合征102例的临床观察[J].中国农村卫生事业管理,2017,37(6):735-737.
[23] 商爱茹.浅析影响更年期综合征患者进行激素替代治疗依从性的原因[J].当代医药论丛,2016,14(4):179-181.
[24] 冯巍,史惠蓉,贾艳艳.激素治疗绝经综合征早期患者的依从性及其影响因素分析[J].中华老年医学杂志,2016,35(7):732-735.
[25] 王燕.影响更年期综合征激素补充治疗依从性相关因素分析[J].山西医药杂志,2015,44(10):1154-1156.
[26] 董小艳.影响更年期综合征激素替代治疗依从性相关因素及预防对策[J].中国医学创新,2015,12(7):45-48.
[27] 杨芹,向雨荷,马国婷,等.维持性血液透析患者认知功能障碍影响因素的Meta分析[J].现代医学,2023,51(9):1235-1245.
[28] BURKHART P V,SABATÉ E.Adherence to long-term therapies:evidence for action[J].J Nurs Scholarsh,2003,35(3):207.
[29] 谢雪梅,高静,柏丁兮,等.老年人多重用药依从性现状及影响因素的Meta分析[J].中国全科医学,2023,26(35):4394-4403.
[30] 贾钰,周紫彤,曹学华,等.中国40~65岁女性围绝经期综合征发生率的Meta分析[J].中国全科医学,2023,26(32):4080-4088.
[31] 韦敏凤.广西地区围绝经期妇女对激素替代治疗的认知及影响因素分析[J].实用妇科内分泌电子杂志,2022,9(9):24-26.
[32] 李晓燕,王陶然,田喜慧.北京市海淀山后地区部分围绝经期女性围绝经期综合征及绝经激素治疗认知度的调查分析[J].山西医药杂志,2019,48(12):1404-1406.
[33] 李长滨,金凤,陶敏芳,等.(围)绝经期综合征患者激素替代治疗依从性及其影响因素分析[J].山东医药,2014,54(18):49-50.
[34] 唐雪梅.围绝经期激素补充疗法依从性影响因素分析[J].临床合理用药杂志,2018,11(34):34-36.
[35] SOARES C N.Mood disorders in midlife women:understanding the critical window and its clinical implications[J].Menopause,2014,21(2):198-206. |